Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Chief Medical Officer | May 25, 2016 | May 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date May 25, 2016 · Filed May 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 20,000 |
Reported balance
After 2017-05-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-05-25 · Grant · Acquired 20,000 · Balance 20,000 F3: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F4: Restricted stock will vest as follows; 6,666 will vest on May 25, 2018 and 6,667 will vest on May 25, 2019 and 2020. F5: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. |
| Common StockSEC Table I · non-derivative | IndirectShares owned by Albitar Oncology Defined Benefit Plan | 60,692 |
Reported balance
Holding disclosure · report date 2016-05-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 60,692 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.15 · Expires 2021-04-20 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2016-05-25 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 200,000 F1: On April 20, 2016, Dr. Albitar was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2016-05-25 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 200,000 F2: On April 28, 2017, Dr. Albitar was granted 200,000 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2016, Dr. Albitar was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F2: On April 28, 2017, Dr. Albitar was granted 200,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F3: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
F4: Restricted stock will vest as follows; 6,666 will vest on May 25, 2018 and 6,667 will vest on May 25, 2019 and 2020.
F5: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2017 Filed May 30, 2017 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036155 · doc4.xml · derivative · entry 4 ALBITAR MAHER · CIK 0001591950 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · security: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · derivative.exercise_date: Restricted stock will vest as follows; 6,666 will vest on May 25, 2018 and 6,667 will vest on May 25, 2019 and 2020. F5 · derivative.expiration_date: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:46 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $7.52 Strike: $7.52 | $1,504,000.00 |
DisclosureSEC source: 0001209191-17-029230 · doc4.xml · derivative · entry 3 ALBITAR MAHER · CIK 0001591950 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-04-28 F2 · derivative.exercise_date: On April 28, 2017, Dr. Albitar was granted 200,000 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 20:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 2,800 | $8.40 | $23,520.00 |
DisclosureSEC source: 0001209191-16-142899 · doc4.xml · nonDerivative · entry 2 ALBITAR MAHER · CIK 0001591950 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned by Albitar Oncology Defined Benefit Plan Disclosed balance after: 60,692 Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 21:48 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 105,300 | $8.20 | $863,460.00 |
DisclosureSEC source: 0001209191-16-142527 · doc4.xml · nonDerivative · entry 3 ALBITAR MAHER · CIK 0001591950 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 22:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 51,000 | $8.21 | $418,710.00 |
DisclosureSEC source: 0001209191-16-141281 · doc4.xml · nonDerivative · entry 4 ALBITAR MAHER · CIK 0001591950 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,300 Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 22:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 9,075 | $8.31 | $75,413.25 |
DisclosureSEC source: 0001209191-16-141281 · doc4.xml · nonDerivative · entry 3 ALBITAR MAHER · CIK 0001591950 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,300 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.